ImmuPharma plc (LON:IMM – Get Free Report)’s stock price was down 6.7% on Wednesday . The company traded as low as GBX 4.50 ($0.06) and last traded at GBX 4.67 ($0.06). Approximately 5,281,667 shares traded hands during trading, a decline of 76% from the average daily volume of 22,218,395 shares. The stock had previously closed at GBX 5 ($0.06).
ImmuPharma Stock Up 25.9 %
The stock has a market cap of £20.45 million, a price-to-earnings ratio of -491.00 and a beta of 1.53. The firm’s 50 day moving average is GBX 2.39 and its two-hundred day moving average is GBX 1.93.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Articles
- Five stocks we like better than ImmuPharma
- How to Calculate Return on Investment (ROI)
- Uber’s Business, Cash Flow, and AI are Why it Will Set a New High
- 3 Fintech Stocks With Good 2021 Prospects
- Weak Guidance from Bristol-Myers Could Be Creating an Opportunity
- Buy P&G Now, Before It Sets A New All-Time High
- These are the 3 Stocks Most Likely to Split in 2025
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
